期刊文献+

Management of Hepatocellular Carcinoma: Updated Review

Management of Hepatocellular Carcinoma: Updated Review
下载PDF
导出
摘要 Hepatocellular carcinoma (HCC) represents one of the most challenging potentially curable tumors with high incidence, prevalence and mortality rates. For proper assessment, prognosis estimation and treatment decisions, at least seven important guidelines and staging systems were designated. Proper treatment needs the interaction of multidisciplinary HCC clinic to choose the most appropriate line of treatment. The different modalities of management include resection (surgery or transplantation), local ablation, chemoembolization, radioembolization and molecular targeted therapies with a wide range of investigational drugs that developed after the FDA approved sorafenib. Downstaging and bridging are two important strategies to manage HCC patients who will undergo liver transplantation to improve their postoperative survival. Finally, survival and prognosis depends on several prognostic factors that are either patient related or tumor related. In our study, we aim to provide an updated comprehensive review of the different aspects of liver cancer management starting from staging systems to the different applied treatment modalities. Hepatocellular carcinoma (HCC) represents one of the most challenging potentially curable tumors with high incidence, prevalence and mortality rates. For proper assessment, prognosis estimation and treatment decisions, at least seven important guidelines and staging systems were designated. Proper treatment needs the interaction of multidisciplinary HCC clinic to choose the most appropriate line of treatment. The different modalities of management include resection (surgery or transplantation), local ablation, chemoembolization, radioembolization and molecular targeted therapies with a wide range of investigational drugs that developed after the FDA approved sorafenib. Downstaging and bridging are two important strategies to manage HCC patients who will undergo liver transplantation to improve their postoperative survival. Finally, survival and prognosis depends on several prognostic factors that are either patient related or tumor related. In our study, we aim to provide an updated comprehensive review of the different aspects of liver cancer management starting from staging systems to the different applied treatment modalities.
出处 《Journal of Cancer Therapy》 2013年第2期536-545,共10页 癌症治疗(英文)
关键词 HEPATOCELLULAR CARCINOMA STAGING Molecular TARGETED THERAPIES Hepatocellular Carcinoma Staging Molecular Targeted Therapies
  • 相关文献

参考文献1

二级参考文献90

  • 1Stewart BW,Kleihues P. World cancer report. Lyon: IARC Press,2003.
  • 2Jemal A,Siegel R,Xu J,Ward E. Cancer statistics,2010. CA Cancer J Clin 2010; 60: 277-300.
  • 3Nordenstedt H,White DL,El-Serag HB. The changing pat- tern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42: S206-S214.
  • 4Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 2010; 16: 390-397.
  • 5Poon RT,Fan ST,Lo CM,Liu CL,Wong J. Long-term sur- vival and pattern of recurrence after resection of small hepa- tocellular carcinoma in patients with preserved liver func- tion: implications for a strategy of salvage transplantation. Ann Surg 2002; 235: 373-382.
  • 6Zhu AX. Systemic therapy of advanced hepatocellular car- cinoma: how hopeful should we be? Oncologist 2006; 11: 790-800.
  • 7Pelletier SJ,Fu S,Thyagarajan V,Romero-Marrero C,Bathe- ja MJ,Punch JD,Magee JC,Lok AS,Fontana RJ,Marrero JA. An intention-to-treat analysis of liver transplantation for he- patocellular carcinoma using organ procurement transplant network data. Liver Transpl 2009; 15: 859-868.
  • 8Cheng AL,Kang YK,Chen Z,Tsao CJ,Qin S,Kim JS,Luo R,Feng J,Ye S,Yang TS,Xu J,Sun Y,Liang H,Liu J,Wang J,Tak WY,Pan H,Burock K,Zou J,Voliotis D,Guan Z. Ef- ficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised,double-blind,placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
  • 9Llovet JM,Ricci S,Mazzaferro V,Hilgard P,Gane E,Blanc JF,de Oliveira AC,Santoro A,Raoul JL,Forner A,Schwartz M,Porta C,Zeuzem S,Bolondi L,Greten TF,Galle PR,Seitz JF,Borbath I,H ussinger D,Giannaris T,Shan M,Moscovici M,Voliotis D,Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
  • 10Nexavar [prescribing information]. Wayne,NJ: Bayer Health- Care Pharmaceuticals Inc.,2009.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部